Table 1.

Clinical features of patients in this study.

No	Age (years)	Sex	Disease	Cr (mg/dL)	Hematuria (/μL)	UP/UCr (g/gCre)	U-β2MG (μg/L)	CRP (mg/dL)	Treatment
1	25	F	IgA nephropathy	10.4	381	3.8	31510	0.07	PSL, HD, LKT
2	57	M	IgA nephropathy	5.4	149	7.6	13185	0.35	mPSL, oral PSL
3	32	M	IgA nephropathy	0.9	140	2.5	95.6	0.11	mPSL, oral PSL
4	20	F	IgA nephropathy	1.0	60	8.2	48.6	0.06	mPSL, oral PSL
5	38	F	IgA nephropathy	1.7	1708	3.4	9378.5	5.09	mPSL, oral PSL
6	20	F	Purpura nephritis	0.7	162	1.1	182.1	0.06	None
7	39	F	Purpura nephritis	0.7	212	2.1	74.2	0.06	Oral PSL
8	63	M	MPO-AAV	9.0	140	0.5	22370	3.43	mPSL, oral PSL
9	39	M	MPO-AAV	13.1	208	3.8	226.8	13.37	mPSL, oral PSL
10	61	M	MPO-AAV	2.9	130	0.8	8471.9	2.82	mPSL, oral PSL
11	68	M	MPO-AAV	2.3	1030	3.8	3064.3	3.83	mPSL, oral PSL
12	77	M	MPO-AAV	3.1	243	3.3	90.6	5.73	mPSL, oral PSL
13	70	M	MPO-AAV	2.3	193	1.3	164.9	5.37	mPSL, oral PSL
14	71	M	MPO-AAV	9.1	457	0.4	47683	2.75	mPSL, oral PSL
15	64	M	PR3-AAV	2.8	285	1.7	523.3	23.55	mPSL, CY
16	64	M	Anti-GBM RPGN	15.4	420	2.4	70121	6.40	mPSL, PE, HD
17	63	F	Lupus nephritis (IV + V)	1.3	281	7.0	337.2	2.03	mPSL

Cr: creatinine; CY: cyclophosphamide; GBM: glomerular basement membrane; HD: hemodialysis; IgA: immunoglobulin A; LKT: living kidney transplantation; MPO-AAV: myeloperoxidase anti-neutrophil cytoplasmic antibody associated vasculitis; mPSL: methyl-prednisolone pulse therapy; PE: plasma exchange; PR3-AAV: proteinase 3 anti-neutrophil cytoplasmic antibody associated vasculitis; PSL: prednisolone; RPGN: rapidly progressive glomerulonephritis; UP/UCr: urine protein to creatinine ratio; U-β2MG: urinary beta2-microglobulin.